Skip to main content Skip to main menu
UF Health University of Florida
Department of Neurology College of Medicine
Join Our Team!
Kyle Rizer

Kyle Rizer

Research Coordinator

Department: MD-NEUROLOGY-MOVEMENT DISORDER
Business Phone: (352) 733-2426
Business Email: kyle.rizer@neurology.ufl.edu

On This Page

Publications

Academic Articles

  1. Efficacy and Safety of Deep Brain Stimulation in Tourette Syndrome: The International Tourette Syndrome Deep Brain Stimulation Public Database and Registry.

    Journal
    JAMA neurology.
    Volume/Issue
    75(3):353-359
    [DOI]
    10.1001/jamaneurol.2017.4317.
    [PMID]
    29340590.
    171 citations PubMed Publisher’s Site

  2. Virtual visits for Parkinson disease: A multicenter noncontrolled cohort.

    Journal
    Neurology. Clinical practice.
    Volume/Issue
    7(4):283-295
    [DOI]
    10.1212/CPJ.0000000000000371.
    [PMID]
    28840919.
    37 citations PubMed Publisher’s Site

  3. Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease: A Randomized Clinical Trial.

    Journal
    JAMA.
    Volume/Issue
    316(1):40-50
    [DOI]
    10.1001/jama.2016.8655.
    [PMID]
    27380342.
    185 citations PubMed Publisher’s Site

  4. The International Deep Brain Stimulation Registry and Database for Gilles de la Tourette Syndrome: How Does It Work?

    Journal
    Frontiers in neuroscience.
    Volume/Issue
    10
    [DOI]
    10.3389/fnins.2016.00170.
    [PMID]
    27199634.
    46 citations PubMed Publisher’s Site

Grants

  1. Phase 2/3 Randomized, Double- Blind, Placebo Controlled Study of BHV-8000 in Participants with Early Perkinson’s Disease (“Protocol”).

    Active

    Role:
    Other
    Funding:
    BIOHAVEN PHARMACEUTICALS

  2. Pridopidine Post Trial Access Protocol in Patients with Huntington’s Disease. (“PTAP”)

    Active

    Role:
    Other
    Funding:
    PRILENIA THERAPEUTICS

  3. A35-009, A Phase 2b/3 Study of Safety and Efficacy of AMX0035 in Progressive Supranuclear Palsy (ORION)

    Active

    Role:
    Other
    Funding:
    AMYLYX PHARMACEUTICALS

  4. A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Arm, Multicenter Study Evaluating the Efficacy and Safety of Pridopidine in Patients with Early Stage of Huntington Disease

    Role:
    Other
    Funding:
    PRILENIA THERAPEUTICS

  5. A Randomized, Double-Blind, Double-Dummy, Active-Controlled Study Comparing the Efficacy, Safety and Tolerability of ABBV-951 to Oral Carbidopa/Levodopa in Advanced Parkinson’s Disease Patients

    Role:
    Other
    Funding:
    ABBVIE

  6. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated with Huntington’s Disease

    Role:
    Other
    Funding:
    HUNTINGTON STUDY GROUP LTD via NEUROCRINE BIOSCIENCES

  7. A Randomized, Double-Blind, Placebo Controlled Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of ABBV-0805 in Patients with Parkinson’s Disease

    Role:
    Other
    Funding:
    ABBVIE

Contact Details

Phones:
Business:
(352) 733-2426
Emails:
Business:
kyle.rizer@neurology.ufl.edu
Addresses:
Business Mailing:
PO Box 112742
 GAINESVILLE FL 32611
Business Street:
3009 SW WILLISTON RD
 GAINESVILLE FL 32608